JP2002517491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517491A5 JP2002517491A5 JP2000553419A JP2000553419A JP2002517491A5 JP 2002517491 A5 JP2002517491 A5 JP 2002517491A5 JP 2000553419 A JP2000553419 A JP 2000553419A JP 2000553419 A JP2000553419 A JP 2000553419A JP 2002517491 A5 JP2002517491 A5 JP 2002517491A5
- Authority
- JP
- Japan
- Prior art keywords
- acid group
- alkyl
- butyl
- ethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 description 10
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19825804.6 | 1998-06-10 | ||
| DE19825804A DE19825804C2 (de) | 1998-06-10 | 1998-06-10 | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| PCT/EP1999/003701 WO1999064410A1 (de) | 1998-06-10 | 1999-05-28 | BENZO(b)THIEPIN-1,1-DIOXIDDERIVATE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND DEREN VERWENDUNG |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002517491A JP2002517491A (ja) | 2002-06-18 |
| JP2002517491A5 true JP2002517491A5 (https=) | 2006-06-29 |
| JP4374426B2 JP4374426B2 (ja) | 2009-12-02 |
Family
ID=7870440
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553419A Expired - Fee Related JP4374426B2 (ja) | 1998-06-10 | 1999-05-28 | ベンゾ（ｂ）チエピン−１，１−ジオキサイド誘導体、その製造方法、これらの化合物を含有する医薬およびその使用 |
| JP2000553418A Expired - Lifetime JP3374129B2 (ja) | 1998-06-10 | 1999-05-29 | ベンゾチエピン−１，１−ジオキサイド誘導体、その製造方法、これらの化合物を含有する医薬およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553418A Expired - Lifetime JP3374129B2 (ja) | 1998-06-10 | 1999-05-29 | ベンゾチエピン−１，１−ジオキサイド誘導体、その製造方法、これらの化合物を含有する医薬およびその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6387944B1 (https=) |
| EP (2) | EP1086092B1 (https=) |
| JP (2) | JP4374426B2 (https=) |
| KR (2) | KR100681721B1 (https=) |
| CN (2) | CN1127497C (https=) |
| AR (2) | AR018634A1 (https=) |
| AT (2) | ATE227715T1 (https=) |
| AU (2) | AU753275B2 (https=) |
| BR (2) | BR9912188B1 (https=) |
| CA (2) | CA2334775C (https=) |
| CZ (2) | CZ297989B6 (https=) |
| DE (3) | DE19825804C2 (https=) |
| DK (2) | DK1086092T3 (https=) |
| ES (2) | ES2182535T3 (https=) |
| HU (2) | HU229761B1 (https=) |
| ID (2) | ID28695A (https=) |
| IL (1) | IL140078A (https=) |
| NO (1) | NO327075B1 (https=) |
| NZ (1) | NZ508681A (https=) |
| PL (2) | PL196074B1 (https=) |
| PT (2) | PT1086092E (https=) |
| RU (2) | RU2215001C2 (https=) |
| TR (2) | TR200003634T2 (https=) |
| WO (2) | WO1999064410A1 (https=) |
| ZA (2) | ZA200007060B (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| US6489366B1 (en) | 1998-12-23 | 2002-12-03 | G. D. Searle, Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| HRP20030498A2 (en) * | 2000-12-21 | 2005-04-30 | Aventis Pharma Deutschland Gmbh | Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| DE10064402A1 (de) * | 2000-12-21 | 2002-06-27 | Aventis Pharma Gmbh | Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| NZ531293A (en) * | 2001-08-22 | 2005-08-26 | Aventis Pharma Gmbh | Pharamceuticals containing 1,4-benzothiepine-1,1-dioxide derivatives and another active substances such as ezetimibe, pamaqueside or tiqueside for treating lipid metabolism and atherosclerotic disorders |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| TWI331143B (en) | 2001-09-08 | 2010-10-01 | Astrazeneca Uk Ltd | Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them |
| BR0306643A (pt) | 2002-01-17 | 2004-10-19 | Pharmacia Corp | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| US20040138145A1 (en) * | 2002-12-12 | 2004-07-15 | Aventis Pharma S.A. | Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| DE102006053636B4 (de) * | 2006-11-14 | 2008-09-18 | Sanofi-Aventis Deutschland Gmbh | Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung |
| DE102006053635B4 (de) * | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US20100221513A1 (en) * | 2008-09-05 | 2010-09-02 | Wisconsin Alumni Research Foundation | Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| PL3400944T3 (pl) | 2010-11-04 | 2020-11-16 | Albireo Ab | Inhibitory ibat w leczeniu chorób wątroby |
| JP6097695B2 (ja) | 2010-11-08 | 2017-03-15 | アルビレオ アクチエボラグ | Ｉｂａｔ阻害剤および胆汁酸結合剤を含む薬学的組み合わせ |
| CN104023727B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
| US20140275090A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| CA2952406A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for preventing or reducing coloration thereof |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| EP3413877B1 (en) | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
| RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| JP2020530448A (ja) | 2017-08-09 | 2020-10-22 | アルビレオ・アクチボラグ | コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用 |
| ES2942443T3 (es) | 2018-06-05 | 2023-06-01 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| ES2955799T3 (es) | 2019-02-06 | 2023-12-07 | Albireo Ab | Compuestos de benzotiazepina y su uso como moduladores de los ácidos biliares |
| HUE060905T2 (hu) | 2019-02-06 | 2023-04-28 | Albireo Ab | Benzotiadiazepin vegyületek és azok alkalmazása epesav modulátorként |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| PL3923943T3 (pl) | 2019-02-12 | 2024-12-09 | Mirum Pharmaceuticals, Inc. | Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| TWI877263B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| CA3158181A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES2973549T3 (es) | 2019-12-04 | 2024-06-20 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores de los ácidos biliares |
| TWI877262B (zh) | 2019-12-04 | 2025-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其作為膽酸調節劑之用途 |
| AR120676A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| TWI867107B (zh) | 2019-12-04 | 2024-12-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
| AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット |
| JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア（ジ）アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| KR20250022025A (ko) | 2022-06-09 | 2025-02-14 | 알비레오 에이비 | 간염 치료 |
| CN119487013A (zh) | 2022-07-05 | 2025-02-18 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| AU2023390975A1 (en) | 2022-12-09 | 2025-06-05 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
| WO2025146507A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2025146508A1 (en) | 2024-01-05 | 2025-07-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| DK0781278T3 (da) * | 1994-09-13 | 2001-04-17 | Monsanto Co | Nye benzothiepiner, som har aktivitet som inhibitorer af ileal galdsyretransport og taurocholatoptagelse |
| NZ331813A (en) * | 1996-03-11 | 2001-03-30 | G | Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| AU5301599A (en) * | 1998-08-20 | 2000-03-14 | Takeda Chemical Industries Ltd. | Quaternary ammonium salts and their use |
-
1998
- 1998-06-10 DE DE19825804A patent/DE19825804C2/de not_active Expired - Lifetime
-
1999
- 1999-05-28 WO PCT/EP1999/003701 patent/WO1999064410A1/de not_active Ceased
- 1999-05-28 DK DK99927784T patent/DK1086092T3/da active
- 1999-05-28 PT PT99927784T patent/PT1086092E/pt unknown
- 1999-05-28 EP EP99927784A patent/EP1086092B1/de not_active Expired - Lifetime
- 1999-05-28 AT AT99927784T patent/ATE227715T1/de active
- 1999-05-28 CN CN99807171A patent/CN1127497C/zh not_active Expired - Fee Related
- 1999-05-28 AU AU45019/99A patent/AU753275B2/en not_active Ceased
- 1999-05-28 JP JP2000553419A patent/JP4374426B2/ja not_active Expired - Fee Related
- 1999-05-28 ID IDW20002562A patent/ID28695A/id unknown
- 1999-05-28 DE DE59903411T patent/DE59903411D1/de not_active Expired - Lifetime
- 1999-05-28 KR KR1020007013964A patent/KR100681721B1/ko not_active Expired - Fee Related
- 1999-05-28 TR TR2000/03634T patent/TR200003634T2/xx unknown
- 1999-05-28 CZ CZ20004592A patent/CZ297989B6/cs not_active IP Right Cessation
- 1999-05-28 US US09/719,047 patent/US6387944B1/en not_active Expired - Lifetime
- 1999-05-28 BR BRPI9912188-3A patent/BR9912188B1/pt not_active IP Right Cessation
- 1999-05-28 RU RU2001101491/04A patent/RU2215001C2/ru not_active IP Right Cessation
- 1999-05-28 HU HU0102256 patent/HU229761B1/hu not_active IP Right Cessation
- 1999-05-28 CA CA002334775A patent/CA2334775C/en not_active Expired - Fee Related
- 1999-05-28 PL PL344827A patent/PL196074B1/pl unknown
- 1999-05-28 ES ES99927784T patent/ES2182535T3/es not_active Expired - Lifetime
- 1999-05-29 IL IL14007899A patent/IL140078A/en not_active IP Right Cessation
- 1999-05-29 ES ES99927802T patent/ES2215387T3/es not_active Expired - Lifetime
- 1999-05-29 ID IDW20002564A patent/ID26876A/id unknown
- 1999-05-29 KR KR1020007013931A patent/KR100562184B1/ko not_active Expired - Lifetime
- 1999-05-29 NZ NZ508681A patent/NZ508681A/en not_active IP Right Cessation
- 1999-05-29 RU RU2001101499/04A patent/RU2220141C2/ru active
- 1999-05-29 PT PT99927802T patent/PT1086113E/pt unknown
- 1999-05-29 CA CA002334773A patent/CA2334773C/en not_active Expired - Lifetime
- 1999-05-29 WO PCT/EP1999/003743 patent/WO1999064409A2/de not_active Ceased
- 1999-05-29 AT AT99927802T patent/ATE259372T1/de active
- 1999-05-29 CZ CZ20004591A patent/CZ297925B6/cs not_active IP Right Cessation
- 1999-05-29 CN CNB998071722A patent/CN1152039C/zh not_active Expired - Lifetime
- 1999-05-29 HU HU0102554A patent/HU228570B1/hu unknown
- 1999-05-29 DE DE59908522T patent/DE59908522D1/de not_active Expired - Lifetime
- 1999-05-29 AU AU45031/99A patent/AU752633B2/en not_active Expired
- 1999-05-29 JP JP2000553418A patent/JP3374129B2/ja not_active Expired - Lifetime
- 1999-05-29 BR BRPI9911123-3A patent/BR9911123B1/pt not_active IP Right Cessation
- 1999-05-29 EP EP99927802A patent/EP1086113B1/de not_active Expired - Lifetime
- 1999-05-29 TR TR2000/03632T patent/TR200003632T2/xx unknown
- 1999-05-29 DK DK99927802T patent/DK1086113T3/da active
- 1999-05-29 PL PL99345901A patent/PL196057B1/pl unknown
- 1999-06-08 AR ARP990102716A patent/AR018634A1/es active IP Right Grant
- 1999-06-08 AR ARP990102715A patent/AR018633A1/es active IP Right Grant
-
2000
- 2000-11-30 ZA ZA200007060A patent/ZA200007060B/xx unknown
- 2000-11-30 ZA ZA200007061A patent/ZA200007061B/en unknown
- 2000-12-08 NO NO20006251A patent/NO327075B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002517491A5 (https=) | ||
| BR0008979A (pt) | Composto quìmico, uso de um composto, método de tratamento, processo de preparação de um composto, composição farmacêutica e método de fabricação da mesma | |
| JP2004533444A5 (https=) | ||
| JP2002501049A5 (https=) | ||
| JP2002525286A5 (https=) | ||
| CA2284732A1 (en) | Analogs of cocaine | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| JP2003535094A5 (https=) | ||
| ATE300941T1 (de) | Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung | |
| EP1772142A3 (en) | Organic compounds | |
| CA2430692A1 (en) | Geldanamycin derivative and use of same to treat cancer | |
| AU2003225617A1 (en) | Thiadiazolylpiperazine derivatives useful for treating or preventing pain | |
| JPH11193282A5 (https=) | ||
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| JP2002527414A5 (https=) | ||
| EP1184034A3 (en) | Oral drug composition containing a verapamil derivative as a drug-absorption promotor | |
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| JP2002521468A5 (https=) | ||
| JP2002522501A5 (https=) | ||
| JP2002506864A5 (https=) | ||
| RU2003134629A (ru) | Соединения цефема | |
| WO1999033450A3 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| EP1857442A3 (en) | Novel antimycobacterial compounds | |
| JP2003520208A5 (https=) | ||
| CA2438509A1 (en) | Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria |